Fernando Membreno, MD
Transplant Hepatology · McAllen, TXNPI 1942233929
Payments from drug & device makers
Across 342 payments — averaging $2151.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$413K
- Gilead$152K
- Madrigal Pharmaceuticals$102K
- Ipsen Biopharmaceuticals, Inc$37K
- Corcept Therapeutics$27K
- E.r. Squibb & Sons, L.L.C.$4K
- plus $2K from 13 others
What the payments were for
- Consulting fees$7,3603%
- Speaking & faculty fees$208,21981%
- Travel & lodging$32,94813%
- Food & beverage$9,3474%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 15 | $412,799 |
| Gilead | 180 | $151,537 |
| Madrigal Pharmaceuticals | 64 | $102,117 |
| Ipsen Biopharmaceuticals, Inc | 43 | $36,842 |
| Corcept Therapeutics | 7 | $26,661 |
| E.r. Squibb & Sons, L.L.C. | 1 | $4,000 |
| Mallinckrodt Hospital Products Inc. | 8 | $380 |
| Melinta Therapeutics, LLC | 4 | $264 |
| Exact Sciences | 3 | $252 |
| AstraZeneca | 4 | $246 |
| Boston Scientific | 3 | $186 |
| Dova Pharmaceuticals | 1 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $100 |
| Boehringer Ingelheim | 1 | $80 |
| Fujifilm Healthcare Americas Corporation | 2 | $58 |
| Novo Nordisk | 2 | $41 |
| AbbVie | 1 | $28 |
| Medtronic | 1 | $21 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$735,743 in reported general payments places this provider in the 75th percentile of 28 transplant hepatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 16 | $1,651 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 12 | $321 |
| Spironolactone | 25 | $205 |
| Furosemide | 15 | $46 |
| Carvedilol | 14 | $19 |
Paid to pharmacies, not to this prescriber.
Other transplant hepatology in McAllen
- Madhavi RudrarajuSan Antonio$8M
- Abdullah MubarakTyler$4.2M
- Mangesh PagadalaDallas$1.9M
- David VictorHouston$1.3M
- Prasun JalalHouston$941K
- Carmen LandaverdeSan Antonio$757K
- Stevan GonzalezFort Worth$515K
- Ruben Hernaez RodriguezHouston$251K
- Hector NazarioDallas$227K
- Saira KhaderiHouston$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.